Instructions to Authors 2014

General Policy. ANTICANCER RESEARCH (AR) will accept original high quality works and reviews on all aspects of experimental and clinical cancer research. The Editorial Policy suggests that priority will be given to papers advancing the understanding of cancer causation, and to papers applying the results of basic research to cancer diagnosis, prognosis, and therapy. AR will also accept the following for publication: (a) Abstracts and Proceedings of scientific meetings on cancer, following consideration and approval by the Editorial Board; (b) Announcements of meetings related to cancer research; (c) Short reviews (of approximately 120 words) and announcements of newly received books and journals related to cancer, and (d) Announcements of awards and prizes.

The principal aim of AR is to provide prompt publication (print and online) for original works of high quality, generally within 1-2 months from final acceptance. Manuscripts will be accepted on the understanding that they report original unpublished works on the cancer problem that are not under consideration for publication by another journal, and that they will not be published again in the same form. All authors should sign a submission letter confirming the approval of their article contents. All material submitted to AR will be subject to review, when appropriate, by two members of the Editorial Board and by one suitable outside referee. The Editors reserve the right to improve manuscripts on grammar and style.

The Editors and Publishers of AR accept no responsibility for the contents and opinions expressed by the contributors. Authors should warrant due diligence in the creation and issuance of their work.

NIH Open Access Policy. The journal acknowledges that authors of NIH funded research retain the right to provide a copy of the final manuscript to the NIH four months after publication in ANTICANCER RESEARCH, for public archiving in PubMed Central.

Copyright. Once a manuscript has been published in ANTICANCER RESEARCH, which is a copyrighted publication, the legal ownership of all published parts of the paper has been transferred from the Author(s) to the journal. Material published in the journal may not be reproduced or published elsewhere without the written consent of the Managing Editor or Publisher.

Format. Two types of papers may be submitted: (i) Full papers containing completed original work, and (ii) review articles concerning fields of recognisable progress. Papers should contain all essential data in order to make the presentation clear. Reasonable economy should be exercised with respect to the number of tables and illustrations used. Papers should be written in clear, concise English. Spelling should follow that given in the “Shorter Oxford English Dictionary”.

Manuscripts. Submitted manuscripts should not exceed fourteen (14) pages (approximately 250 words per double-spaced typed page), including abstract, text, tables, figures, and references (corresponding to 4 printed pages). Papers exceeding four printed pages will be subject to excess page charges. All manuscripts should be divided into the following sections: (a) First page including the title of the presented work [not exceeding fifteen (15) words], full names and full postal addresses of all Authors, name of the Author to whom proofs are to be sent, key words, an abbreviated running title, an indication “review”, “clinical”, “epidemiological”, or “experimental” study, and the date of submission. (Note: The order of the Authors is not necessarily indicative of their contribution to the work. Authors may note their individual contribution(s) in the appropriate section(s) of the presented work); (b) Abstract not exceeding 150 words, organized according to the following headings: Background/Aim - Materials and Methods/Patients and Methods - Results - Conclusion; (c) Introduction; (d) Materials and Methods/Patients and Methods; (e) Results; (f) Discussion; (g) Acknowledgements; (h) References. All pages must be numbered consecutively. Footnotes should be avoided. Review articles may follow a different style according to the subject matter and the Author’s opinion. Review articles should not exceed 35 pages (approximately 250 words per double-spaced typed page) including all tables, figures, and references.

Figures. All figures (whether photographs or graphs) should be clear, high contrast, at the size they are to appear in the journal: 8.00 cm (3.15 in.) wide for a single column; 17.00 cm (6.70 in.) for a double column; maximum height: 20.00 cm (7.87 in.). Graphs must be submitted as photographs made from drawings and must not require any artwork, typesetting, or size modifications. Symbols, numbering and lettering should be clearly legible. The number and top of each figure must be indicated. Colour plates are charged.

Tables. Tables should be typed double-spaced on a separate page, numbered with Roman numerals and should include a short title.


Clinical Trials. Authors of manuscripts describing clinical trials should provide the appropriate clinical trial number in the correct format in the text.

For International Standard Randomised Controlled Trials (ISRCTN) Registry (a not-for-profit organization whose registry is administered by Current Controlled Trials Ltd.) the unique number must be provided in this format: ISRCTNXXXXXXX (where XXXXXXX represents the unique number, always prefixed by “ISRCTN”). Please note that there is no space between the prefix “ISRCTN” and the number. Example: ISRCTN47956475.

For Clinicaltrials.gov registered trials, the unique number must be provided in this format: NCTXXXXXXX (where XXXXXXX represents the unique number, always prefixed by 'NCT'). Please note that there is no space between the prefix 'NCT' and the number. Example: NCT00001789.

Ethical Policies and Standards. ANTICANCER RESEARCH agrees with and follows the "Uniform Requirements for Manuscripts Submitted to Biomedical Journals" established by the International Committee of Medical Journal Editors in 1978 and updated in October 2001 (www.icmje.org). Microarray data analysis should comply with the "Minimum Information About Microarray Experiments (MIAME) standard". Specific guidelines are provided at the "Microarray Gene Expression Data Society" (MGED) website. Presentation of genome sequences should follow the guidelines of the NHGRI Policy on Release of Human Genomic Sequence Data. Research involving human beings must adhere to the principles of the Declaration of Helsinki and Title 45, U.S. Code of Federal Regulations, Part 46, Protection of Human Subjects, effective December 13, 2001. Research involving animals must adhere to the Guiding Principles in the Care and Use of Animals approved by the Council of the American Physiological Society. The use of animals in biomedical research should be under the careful supervision of a person adequately trained in this field and the animals must be treated humanely at all times. Research involving the use of human foetuses, foetal tissue, embryos and embryonic cells should adhere to the U.S. Public Law 103-41, effective December 13, 2001.

Submission of Manuscripts. Please follow the Instructions to Authors regarding the format of your manuscript and references. There are 3 ways to submit your article (NOTE: Please use only one of the 3 options. Do not send your article twice): 1. To submit your article online please visit: IIAR-Submissions (http://www.iiar-anticancer.org/submissions/login.php) 2. You can send your article via e-mail to journals@iiar-anticancer.org. Please remember to always indicate the name of the journal you wish to submit your paper. The text should be sent as a Word document (*doc) attachment. Tables, figures and cover letter can also be sent as e-mail attachments. 3. You can send the manuscript of your article via regular mail in a USB stick, DVD, CD or floppy disk (including text, tables and figures) together with three hard copies to the following address: John G. Delinasios International Institute of Anticancer Research (IIAR) Editorial Office of ANTICANCER RESEARCH, IN VIVO, CANCER GENOMICS and PROTEOMICS, 1st km Kapanbritiou-Kalamou Road P.O. Box 22, GR-19014 Kapandriti, Attiki GREECE Submitted articles will not be returned to Authors upon rejection.

Galley Proofs. Unless otherwise indicated, galley proofs will be sent to the first-named Author of the submission. Corrections of galley proofs should be limited to typographical errors. Reprints, PDF files, and/or Open Access may be ordered after the acceptance of the paper. Requests should be addressed to the Editorial Office.

Copyright© 2014 - International Institute of Anticancer Research (J.G. Delinasios). All rights reserved (including those of translation into other languages). No part of this journal may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, microfilming, recording or otherwise, without written permission from the Publisher.
The Need for Surgery in Acute Abdominal Pain: A Randomized Study of Abdominal Computed Tomography. P. JUVONEN, T. LEHTIM


Comparative Study of Prescribing Patterns of Tigecycline for Trial-Patients versus Non-Trial-Patients. J.J. HORSCHT, J.B. ZIMMERMANN, ROUFFIAC, O. BAWA, I. LEGUERNEY, P. OPOLON, G. VASSAL, B. GEOERGER

Increased DNA Integrity in Colorectal Cancer. G. LESZINSKI, J. LEHNER, U. GEZER, S. HOLDENRIEDER

Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (Graz, Austria)


Antioxidant Effects of Lipophilic Tea Polyphenols on Diethylnitrosamine/Phenobarbital-induced Hepatocarcinogenesis in Rats. F. ZHOU, T. S. HIRAJIMA, M. TSUJIURA, T. KAWAGUCHI, M. MIYAMAE, H. NAGATA, H. KONISHI, A. SHIOZAKI, E. OTSUJI

Circulating miR-18a; A Sensitive Cancer Screening Biomarker in Human Cancer. S. KOMATSU, D. ICHIKAWA, H. TAKESHITA, R. MORIMURA, HELMERSSON-KARLQVIST, T. GORDH, A. LARSSON


Inhibitory Action of Levocetirizine on the Production of Eosinophil Chemoattractants RANTES and Eotaxin In Vitro and In Vivo. A. KANEI, K. ASANO, K.-I. KANA, A. FURUTA, K. SASAKI, H. SUZAKI (Tokyo; Yokohama, Japan)

Poor Memory Performance in Aged Cynomolgus Monkeys with Hippocampal Atrophy, Depletion of Amyloid Beta 1-42 and Accumulation of Tau Proteins in Cerebrospinal Fluid. H.S. DARUSMAN, J. PANDELAKI, R. MULYADI, D. SAJUTHI, I.A. PUTRI, O.H. KALLIOKOSKI, J. CALL, K.S.P. ABELSON, S.J. SCHAFIRO, A GJEDDE, J. HAU (Copenhagen; Aarhus, Denmark; Jakarta; Bogor, Indonesia; Leipzig, Germany; Bastrop, TX; Baltimore, MD, USA; Montreal, QC, Canada)


Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK ( Graz, Austria)

Increased DNA Integrity in Colorectal Cancer. G. LESZINSKI, J. LEHNER, U. GEZER, S. HOLDENRIEDER (Munich; Bonn, Germany; Istanbul, Turkey)

Circulating Human Fractalkine is Decreased Post-operatively After Orthopedic and Coronary Bypass Surgery. T. EKERFELDT, J. HELMERSSON-KARLOQUIST, T. GORDH, A. LARSSON ( Uppsala, Sweden)

Circulating miR-18a; A Sensitive Cancer Screening Biomarker in Human Cancer. S. KOMATSU, D. ICHIKAWA, H. TAKESHITA, R. MORIMURA, S. HIRAJIMA, M. TSUJIURA, T. KAWAGUCHI, M. MIYAMAE, H. NAGATA, H. KONISHI, A. SHIOZAKI, E. OTSUJI (Kyoto, Japan)

Antioxidant Effects of Polihexanide and Polyethylene glycol in an In-vitro Study in Chronic Rhinosinusitis. R. BIRK, J. GROSSBAIER, C. ADERHOLD, J. STERN-STRÁTER, K. HÖRMANN, A. SAUTER, J.U. SOMMER ( Heidelberg, Germany)

Anti-UV Activity of Kampo Medicines and Constituent Plant Extracts: Re-evaluation with Skin Keratinocyte System. T. KATO, S. HI NO, N. HORIE, T. SHIMOYAMA, T. KANEKO, K. KUSAMA, H. SAKAGAMI

Selection of Recent Articles


Establishment and Characterization of New Orthotic and Metastatic Neuroblastoma Models. E. DAUDIGÉOS-DUBUS, L. LE DRET, V. ROUFFIAC, O. BAWA, I. LEGUERNEY, P. OPOLON, G. VASSAL, B. GEOERGER (Orsay; Villejuif, France)

Comparative Study of Prescribing Patterns of Tigecycline for Trial-Patients versus Non-Trial-Patients. J.J. HORSCHT, J.B. ZIMMERMANN, M.A. WEIGAND, T. BRUCKNER, E.O. MARTIN, T. HOPPE-TICHY, S. SWOBODA (Heidelberg; Gießen, Germany)

Effects of the Bifunctional Sulfoxide MMS350, A Radiation Mitigator, on Hematopoiesis in Long-Term Bone Marrow Cultures and on Radioresistance of Marrow Stromal Cell Lines. A. SHINDE, M.W. EPPERLY, S. CAO, D. FRANICOLA, D. SHIELDS, H. WANG, P. WIPF, S. LI, J.S. GREENBERGER (Pittsburgh, PA, USA)


Inhibitory Action of Levocetirizine on the Production of Eosinophil Chemoattractants RANTES and Eotaxin In Vitro and In Vivo. A. KANEI, K. ASANO, K.-I. KANA, A. FURUTA, K. SASAKI, H. SUZAKI (Tokyo; Yokohama, Japan)

Poor Memory Performance in Aged Cynomolgus Monkeys with Hippocampal Atrophy, Depletion of Amyloid Beta 1-42 and Accumulation of Tau Proteins in Cerebrospinal Fluid. H.S. DARUSMAN, J. PANDELAKI, R. MULYADI, D. SAJUTHI, I.A. PUTRI, O.H. KALLIOKOSKI, J. CALL, K.S.P. ABELSON, S.J. SCHAFIRO, A GJEDDE, J. HAU (Copenhagen; Aarhus, Denmark; Jakarta; Bogor, Indonesia; Leipzig, Germany; Bastrop, TX; Baltimore, MD, USA; Montreal, QC, Canada)


Malignant Ascites in Ovarian Cancer and the Role of Targeted Therapeutics. E. SMOLLE, V. TAUCHER, J. HAYBAECK (Graz, Austria)

Increased DNA Integrity in Colorectal Cancer. G. LESZINSKI, J. LEHNER, U. GEZER, S. HOLDENRIEDER (Munich; Bonn, Germany; Istanbul, Turkey)

Circulating Human Fractalkine is Decreased Post-operatively After Orthopedic and Coronary Bypass Surgery. T. EKERFELDT, J. HELMERSSON-KARLOQUIST, T. GORDH, A. LARSSON (Uppsala, Sweden)

Circulating miR-18a; A Sensitive Cancer Screening Biomarker in Human Cancer. S. KOMATSU, D. ICHIKAWA, H. TAKESHITA, R. MORIMURA, S. HIRAJIMA, M. TSUJIURA, T. KAWAGUCHI, M. MIYAMAE, H. NAGATA, H. KONISHI, A. SHIOZAKI, E. OTSUJI (Kyoto, Japan)

Antioxidant Effects of Polihexanide and Polyethylene glycol in an In-vitro Study in Chronic Rhinosinusitis. R. BIRK, J. GROSSBAIER, C. ADERHOLD, J. STERN-STRÁTER, K. HÖRMANN, A. SAUTER, J.U. SOMMER (Heidelberg, Germany)

Anti-UV Activity of Kampo Medicines and Constituent Plant Extracts: Re-evaluation with Skin Keratinocyte System. T. KATO, S. HI NO, N. HORIE, T. SHIMOYAMA, T. KANERO, K. KUSAMA, H. SAKAGAMI (Saitama; Tokyo, Japan)
A Selection of Recent Papers


Crucial and Novel Cancer Drivers in a Mouse Model of Triple-Negative Breast Cancer. J.P.S. JOHNSON, P. KUMAR, M. KOULNIS, M. PATEL, K. SIMIN (Worcester, MA; Bethesda, MD; Scranton, PA; New York, NY, USA; Singapore, Singapore)

Cilia Gene Expression Patterns in Cancer. M. SHPAK, M.M. GOLDBERG, M.C. COWPERTHW AITE (Austin TX, USA)

MicroRNA-150 Is Up-regulated in Extranodal Marginal Zone Lymphoma of MALT Type. N. GEBAUER, J. KUBA, A. SENFT, A. SCHILLERT, V. BERNARD, C. THORNS (Lübeck, Germany)


Fucoidan-dependent Increased Membrane Component in HepG2: Effect of Fucoidan Is Not Due to Gene Expression. K. HAYAKAWA, T. NAGAMINE (Tokyo; Gunma, Japan)


A Novel Transmembrane Glycoprotein Cancer Biomarker Present in the X Chromosome. A.P. DELGADO, S. HAMID, P. BRANDAO, R. NARAYANAN (Boca Raton, FL, USA)

Rho Kinase Proteins Regulate Global miRNA Expression in Endothelial Cells. J.M. STILES, V. KURISETTY, D.C. MITCHELL, B.A. BRYAN (El Paso, TX, USA)

Gene Expression Profiling of Circulating Natural Killer Cells in Head and Neck Squamous Cell Carcinoma. A. BOTTCHER, J. OSTWALD, D. KOCZAN, R. KNECHT, B. KRAMP, S. DOMMERICH (Hamburg; Rostock; Berlin, Germany)


Isolation of Stem Cells Using Spheroids from Fresh Surgical Specimen: An Analytic Mini-review. I. AVITAL, A. STOJADINOVIC, H. WANG, C. MANNION, W.C.S. CHO, J. WANG, Y.G. MAN (Richmond, VA; Hackensack, NJ; Washington, DC, USA; Hangzhou, China; Hong Kong, Hong Kong)

Predictive and Prognostic Significance of Sodium Levels in Patients with NSCLC Treated by Erlotinib. M. SVATON, O. FIALA, M. PESEK, F. BRUHA, P. MUKENSNABL, J. RACEK, M. MINARIK, Z. BORTLICEK (Prague; Brno, Czech Republic) ................................................................. 7461

Clinicopathological Factors Affecting Progression-Free Survival of Patients With Previously Treated Advanced Non-Small Cell Lung Cancer After S-1 Therapy With or Without Bevacizumab. K. MASAGO, S. FUJITA, A. HATA, R. KAJI, K. OHTSUKA, C. OKUDA, J. TAKESHITA, N. KATAKAMI (Kobe; Nagoya, Japan) 7467


Appendix to Anticancer Research Vol. 34, No 10, October 2014. Abstracts of the 9th International Conference of Anticancer Research, October 6-10, 2014, Sithonia, Greece ................................................................. 7479

Errata ............................................................................................................................................ 7485

Index............................................................................................................................................. 7487
Assessment of Risk of Late Rectal Bleeding for Patients with Prostate Cancer Started on Anticoagulation Before or After Radiation Treatment. D. SCHREIBER, S.-C. CHEN, J. RINEER, M. WORTH, T. TELIVALA, D. SCHWARTZ (New York; Brooklyn, NY; Orlando, FL, USA) ........................................... 7367

Frequency and Predisposing Factors for Interfractional Rectal Displacement Requiring Repeated Precaution in Prostate Cancer Patients Treated with Image-Guided Intensity-Modulated Radiation Therapy. K. IWAMA, H. YAMAZAKI, T. NISHIMURA, Y. OOTA, N. AIBE, S. NAKAMURA, H. IKENO, K. YOSHIDA, H. OKABE (Kyoto; Osaka, Japan) ........................................ 7373

Palifermin in Children Undergoing Autologous Stem Cell Transplantation: a Matched-pair Analysis. K. CZYZEWSKI, R. DEBSKI, A. KRENSKA, M. WYSOCKI, J. STYCZYNSKI (Bydgoszcz, Poland) ........ 7379

Analysis of Intrafractional Organ Motion by Megavoltage Computed Tomography in Patients with Lung Cancer Treated with Image-guided Stereotactic Body Radiotherapy Using Helical Tomotherapy. N. AIBE, H. YAMAZAKI, T. NISHIMURA, Y. OOTA, K. IWAMA, S. NAKAMURA, H. IKENO, K. YOSHIDA, H. OKABE, K. YAMADA (Kyoto; Osaka, Japan) ........................................ 7383

Risk Factors for Pericardial Effusion in Patients with Stage I Esophageal Cancer Treated with Chemoradiotherapy. K. TAMARI, F. ISOHASHI, Y. AKINO, O. SUZUKI, Y. SEO, Y. YOSHIOKA, Y. HAYASHI, T. NISHIDA, T. TAKEHARA, M. MORI, Y. DOKI, K. OGAWA (Osaka, Japan) ........... 7389

Ponticulus posticus is a Frequent Radiographic Finding on Lateral Cephalograms in Nevoid Basal Cell Carcinoma Syndrome (Gorlin–Goltz Syndrome). R.E. FRIEDRICH (Hamburg, Germany) ........................................... 7395

Does Pulmonary Resection Promote the Progression of Unresected Ground-glass Nodules? K. UEDA, F. SANO, J. MURAKAMI, M. HAYASHI, T. KOBAYASHI, Y. KUNIHIRO, K. HAMANO (Yamaguchi, Japan) ........ 7401


Analysis of Preoperative Serum Levels of MMP1, -2, and -9 in Patients with Site-specific Head and Neck Squamous Cell Cancer. D. KALFERT, M. LUDVIKOVÁ, O. TOPOLCAN, J. WINDRICHOVÁ, E. MALIROVA, M. PESTA, P. CEŁAKOVSKÝ (Prague; Pilsen; Hradec Kralove, Czech Republic) ........... 7431

Kinetics of Circulating Levels of miR-195, miR-155 and miR-21 in Patients with Breast Cancer Undergoing Mastectomy. M. IGGLÉZOU, K. VARELI, G.K. GEORGIIOU, I. SAINIS, E. BRIASOULIS (Ioannina, Greece) ........... 7443


Esophageal Carcinosarcoma: Management and Prognosis at a Single Italian Series. F. CAVALLIN, M. SCARPA, R. ALFIERI, M. CAGOL, A. RUOL, M. RUGGE, E. ANCONA, C. CASTORO (Padua, Italy) ...................................................... 7455

Contents continued on the preceding page
Portal Vein Embolisation with Application of Haematopoietic Stem Cells in Patients with Primarily or Non-resectable Colorectal Liver Metastases. V. TRESKA, V. LISKA, J. FICHTL, D. LYSAK, H. MIRKA, J. BRUHA, P. DURAS, I. TRESKOVA, J. NAHLIK, V. SIMANEK, O. TOPOLCAN (Pilsen, Czech Republic) ................................................................. 7279

Febuxostat for Management of Tumor Lysis Syndrome Including its Effects on Levels of Purine Metabolites in Patients with Hematological Malignancies - A Single Institution’s, Pharmacokinetic and Pilot Prospective Study. M. TAKAI, T. YAMAUCHI, M. OOKURA, Y. MATSUDA, K. TAI, S. KISHI, A. YOSHIDA, H. IWASAKI, T. NAKAMURA, T. UEDA (Fukui, Japan) ........................................................................................................... 7287

Feasibility Study of Supportive Care Using Lafutidine, a Histamine H2 Receptor Antagonist, to Prevent Gastrointestinal Toxicity During Chemotherapy for Gastric Cancer. T. NAMIKAWA, E. MUNEKAGE, H. MAEDA, H. KITAGAWA, M. KOBAYASHI, K. HANAZAKI (Kochi, Japan) ........................................ 7297

Ovarian Sarcoma Carries a Poorer Prognosis than Ovarian Epithelial Cancer Throughout all FIGO Stages: A Single-center Case–control Matched Study. N. BACALBASA, I. BALESCU, S. DIMA, I. POPESCU (Bucharest, Romania) ..................................................................................................................... 7303

Comparison of Two Dose Levels of Stereotactic Radiosurgery for 1-3 Brain Metastases from Non-small Cell Lung Cancer. D. RADES, S. HUTTENLOCHER, M. DAHLKE, D. HORNUNG, O. BLANCK, P.V. THAI, N.T. TRANG, M.T. KHOA, S.E. SCHILD (Lübeck; Hamburg; Güstrow, Germany; Hanoi, Vietnam; Scottsdale, AZ, USA) ........................................................................................................... 7309


Radiation Recall Gastritis Secondary to Erlotinib in a Patient with Pancreatic Cancer. C. GRAZIANI, S. HEGDE, M.W. SAIF (Boston, MA, USA) .......................................................................................................................... 7339

Two-team Simultaneous Total Radical Vulvectomy and Inguino-femoral Lymphadenectomy via Separate Incisions for Locally Advanced (FIGO Stages IB ≥4 cm–III) Squamous Vulvar Cancer. M. FAMBRINI, F. SORBI, G. SISTI, V. CHECUCCI, G. CARITI, V. SCOTTI, E. TINACCI, I. TURRINI, M. MICAGLIO, A. DE MAGNIS (Florence, Italy) .......................................................................................................................... 7345

Expression of Adhesion Molecules and the Proliferative Activity of Carcinosarcoma of the Ovary. H. HIRANO, T. KIZAKI, T. ITO, A. OKIMURA, K. YAMANEGI, K. NAKASHO (Hyogo, Japan) ........................................................................................................... 7351

A Case Series of Patients with HER2-Overexpressed Primary Metastatic Gastroesophageal Adenocarcinoma. P. CINAR, S.M. CALKINS, A.P. VENOOK, R.K. KELLEY (San Francisco, CA, USA) ........................................................................................................... 7357


Contents continued on the preceding page
Clinical Studies

In Vitro Chemoresponse in Metachronous Pairs of Ovarian Cancers. H.J. DALTON, J.V. FIORICA, R.P. EDWARDS, I. BENJAMIN, R.P. ROCCONI, F.O. RECIO, J.L. LOVECCHIO, M.O. BURRELL, M.S. SHAHIN, E.C. GRENDYS, D. WANG, T. WANG, B.J. MONK (Houston, TX; Sarasota; Boca Raton; Fort Myers, FL; Pittsburgh; Abington, PA; Phoenix, AZ; Mobile, AL; Manhasset, NY; Atlanta, GA, USA).............

Independence of Cytotoxic Drug Sensitivity Profiles and Receptor Subtype of Invasive Ductal Breast Carcinoma Demonstrated by the Histoculture Drug Response Assay (HDRA). K.Y. KIM, B.W. CHUNG, I. YANG, M.B. KIM, R.M. HOFFMAN (Seoul, Republic of Korea; San Diego, CA, USA) ............

Estrogen and Androgen Receptors in Inflammatory Fibroid Polyp (Vanek’s Tumor): Case Report. Z. JUKIC, Z. FERENCIC, P. RADULOVIC, A. MIJIC, A. FUCIC (Nova Gradiska; Zagreb, Croatia)................


Clinical Significance of an Inflammation-based Prognostic System for Gastric Cancer Patients with a Preoperative Normal Serum Level of Carcinoembryonic Antigen. M. ISHIZUKA, Y. OYAMA, A. ABE, K. TAGO, G. TANAKA, K. KUBOTA (Tochigi, Japan) ..........................................................................

Outcome of Esophagojejunostomy During Totally Laparoscopic Total Gastrectomy: A Single-Center Retrospective Study. Y. HIYOSHI, E. OKI, K. ANDO, S. ITO, H. SAEKI, M. MORITA, H. BABA, Y. MAEHARA (Fukuoka; Kumamoto, Japan) ........................................................................................

Simultaneous 24 h-Infusion of High-dose 5-Fluorouracil and Sodium-Folinate as Alternative to Capecitabine in Advanced Breast Cancer. A. TERJUNG, S. KUMMER, M. FRIEDRICH (Krefeld, Germany) ..............

Concomitant Capecitabine with Hepatic Delivery of Drug Eluting Beads in Metastatic Colorectal Cancer. O. AKINWANDE, A. MILLER, D. HAYES, R. O’HARA, D. TOMALTY, R.C.G. MARTIN (Pittsburgh, PA; Louisville, KY; Little Rock, AR; Colorado Springs, CO; Huntsville, AL, USA) ................................

Comparison of Two Transarterial Chemoembolization Strategies for Hepatocellular Carcinoma. J. TAVERNIER, P. FAGNONI, P. CHABROT, B. GUIU, L. VADOT, S. AHO, L. BOYER, A. ABERGEL, P. HILLON, V. SAUTOU, M. BOULIN (Clermont-Ferrand; Dijon, France) ...........................................

Synthesis of a Monofunctional Platinum Compound and its Activity Alone and in Combination with Phytochemicals in Ovarian Tumor Models. L. ARZUMAN, P. BEALE, J.Q. YU, N. PROSCHOOGO, F. HUQ (Lidcombe; Concord; Sydney, NSW, Australia) ........................................................................... 7077

Cleaved CD147 Shed from the Surface of Malignant Melanoma Cells Activates MMP2 Produced by Fibroblasts. M. HATANAKA, Y. HIGASHI, T. FUKUSHIGE, N. BABA, K. KAWAI, T. HASHIGUCHI, J. SU, W. ZENG, X. CHEN, T. KANEKURA (Kagoshima, Japan; Changsha, PR China) .................. 7091

Tanshinone IIA Inhibits Gastric Carcinoma AGS Cells Through Increasing p-p38, p-JNK and p53 but Reducing p-ERK, CDC2 and Cyclin B1 Expression. C.-C. SU (Changhua; Taichung, Taiwan, ROC) .......................... 7097

Cisplatin at Sub-toxic Levels Mediates Integrin Switch in Lung Cancer Cells. A. MAIUTHED, P. CHANVORACHOTE (Bangkok, Thailand) ........................................................................................................ 7111


A Positive Correlation Between Neutrophils in Regional Lymph Nodes and Progression of Gastric Cancer. M. TOKUMOTO, H. TANAKA, M. OHIRA, Y. GO, Y. OKITA, K. SAKURAI, T. TOYOKAWA, N. KUBO, K. MUGURUMA, K. MAEDA, T. SAWADA, K. HIRAKAWA (Osaka, Japan) .............................................. 7129

The Potential of SIRT6 and SIRT7 as Circulating Markers for Head and Neck Squamous Cell Carcinoma. C.-T. LU, C.-M. HSU, P.-M. LIN, C.-C. LAI, H.-C. LIN, C.-H. YANG, H.-H. HSIAO, Y.-C. LIU, H.Y.-H. LIN, S.-F. LIN, M.-Y. YANG (Kaohsiung City; Taoyuan, Taiwan, ROC) ................................................................................................................................. 7137

Induction of Apoptosis by Eicosapentaenoic Acid in Esophageal Squamous Cell Carcinoma. K. MIZOGUCHI, H. ISHIGURO, M. KIMURA, H. TAKAHASHI, N. SAKAMOTO, T. TANAKA, H. TAKEYAMA (Nagoya, Japan) .......................................................................................................................................................... 7145

Cell-cycle Disturbance and Induction of Programmed Death by New Formamidine Analogs of Daunorubicin. M. STOJAK, M. ŁUKAWSKA, I. OSZCZAPOWICZ, M. OPYDO-CHANEK, L. MAZUR (Kraków; Warsaw, Poland) .............................................................................................................................................. 7151

Comparison of Prostate Cancer Gene 3 Score, Prostate Health Index and Percentage Free Prostate-specific Antigen for Differentiating Histological Inflammation from Prostate Cancer and Other Non-neoplastic Alterations of the Prostate at Initial Biopsy. S. DE LUCA, R. PASSERA, E. BOLLITO, M. MANFREDI, R.M. SCARPA, A. SOTTILE, D.F. RANDONE, F. PORPIGLIA (Torino; Candiolo, Italy) .......................................................... 7159

PSCA and MUC1 Gene Polymorphisms Are Linked with Gastric Cancer and Pre-malignant Gastric Conditions. J. KUPCINSKAS, T. WEX, A. LINK, R. BARTUSEVICIUTE, M. DEDELAITE, G. KEVALAITE, M. LEJA, J. SKIECEVICIENE, G. KUDELIS, L. JONAITIS, L. KUPCINSKAS, P. MALFERTHEINER (Kaunas, Lithuania; Magdeburg, Germany; Riga, Latvia) ................................................................. 7167

An Improved and Versatile Immunosuppression Protocol for the Development of Tumor Xenograft in Mice. M. JIVRAJANI, M.V. SHAIKH, N. SHRIVASTAVA, M. NIVSARKAR (Ahmedabad, India) ........................................................... 7177

Regulatory T-Cells and Micrometastasis in Lymph Nodes of Stage I NSCLC. T. HANAGIRI, M. FUKUMOTO, Y. KOYANAGI, Y. FURUTANI, F. TANAKA (Fukuoka; Kitakyushu, Japan) ........................................................................................................................................... 7185

Contents continued on the preceding page
Evaluation of a Special Combination of Glucan with Organic Selenium Derivative in Different Murine Tumor Models. V. VETVICKA, M. F. PINATTO-BOTELHO, A.A. DOS SANTOS, C.A.F. DE OLIVEIRA (Louisville, KY, USA.; São Paulo; Lençóis Paulista, SP, Brazil) .......................................................... 6939

Differential Spheroid Formation by Oral Cancer Cells. CARLIN LEE, CASEY LEE, A. ATAKILIT, A. SIU, D.M. RAMOS (San Francisco, CA; San Antonio, TX, USA) ............................................................ 6945

A Novel Cytidine Analog, RX-3117, Shows Potent Efficacy in Xenograft Models, even in Tumors that Are Resistant to Gemcitabine. M.Y. YANG, Y.B. LEE, C.-H. AHN, J. KAYE, T. FINE, R. KASHI, O. OHNE, K. SMID, G.J. PETERS, D.J. KIM (Rochville, MD, USA; Petach Tikva, Israel; Amsterdam, The Netherlands) .... 6951

Expression of MSH2 and MSH6 on a Tissue Microarray in Patients with Osteosarcoma. T. JENTZSCH, B. ROBL, M. HUSMANN, B. BODE-LESNIEWSKA, B. FUCHS (Zürich, Switzerland) .......................... 6961

p53 Up-regulation During Colorectal Carcinogenesis. C.A. RUBIO, M. RODESJÖ, A. DUVANDER, M. MATHIES, L. GARBERG, J. SHETYE (Stockholm, Sweden) .............................................................. 6973

Inhibition of P-TEFb by DRB Suppresses SIRT1/CK2α Pathway and Enhances Radiosensitivity of Human Cancer Cells. Z.-Q. WANG, C.L. JOHNSON, A. KUMAR, D.P. MOLKENTINE, J.M. MOLKENTINE, T. RABIN, K.A. MASON, L. MILAS, U. RAJU (Houston, TX, USA) ..................................................... 6981


MAD2 Expression in Oral Squamous Cell Carcinoma and its Relationship to Tumor Grade and Proliferation. C. RIZZARDI, L. TORELLI, M. SCHNEIDER, F. GIUDICI, L. ZANDONA, M. BIASOTTO, R. DI LENARDA, M. MELATO (Trieste; Gorizia, Italy) ................................................................. 7021

The \(N\)-Nitrosodiethylamine Mouse Model: Sketching a Timeline of Evolution of Chemically-induced Hepatic Lesions. R.M.G DA COSTA, N. PAULA-SANTOS, A. FAUSTINO ROCHA, A. COLAÇO, C. LOPES, P.A. OLIVEIRA (Porto; Vila Real; Vairão, Portugal) .................................................. 7029


Lectin Histochemistry of Murine WAP-T Mammary Cancer Reveals Similar Glycoconjugate Changes to Those in Human Breast Cancer. S. SCHREIBER, A. GOCHT, F. WEGWITZ, W. DEPPERT, U. SCHUMACHER (Hamburg; Lübeck, Germany) ................................................................. 7045

In Vitro Oxygen Availability Modulates the Effect of Artesunate on HeLa cells. J. MURRAY, S. GANNON, S. RAWE, J.E.J. MURPHY (Sligo; Dublin, Ireland) ................................................................. 7055

Incomplete Epithelial–Mesenchymal Transition in p16-positive Squamous Cell Carcinoma Cells Correlates with \(\beta\)-Catenin Expression. C. UMBREIT, J. FLANJAK, C. WEISS, P. ERBEN, C. ADERHOLD, A. FABER, J. STERN-STRAETER, K. HOERMANN, J.D. SCHULTZ (Mannheim, Germany) ......................... 7061

Contents continued on the preceding page